Clinical implications of pharmacokinetics of sunitinib malate and N-desethyl-sunitinib plasma concentrations for treatment outcome in metastatic renal cell carcinoma patients
暂无分享,去创建一个
T. Habuchi | N. Tsuchiya | M. Miura | S. Satoh | T. Niioka | M. Saito* | Mingguo Huang | T. Inoue | S. Narita | N. Fujiyama | K. Numakura | H. Tsuruta | Makoto Takahashi | Ryoma Igarashi | Atsushi Maeno | Takamitsu Inoue
[1] H. Guchelaar,et al. Assessment of ethnic differences in sunitinib outcome between Caucasian and Asian patients with metastatic renal cell carcinoma: a meta-analysis , 2017, Acta oncologica.
[2] T. Habuchi,et al. Clinical effects of single nucleotide polymorphisms on drug-related genes in Japanese metastatic renal cell carcinoma patients treated with sunitinib , 2017, Anti-cancer drugs.
[3] A. Boddy,et al. Monte Carlo simulations of the clinical benefits from therapeutic drug monitoring of sunitinib in patients with gastrointestinal stromal tumours , 2016, Cancer Chemotherapy and Pharmacology.
[4] R. Motzer,et al. Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal Tumor , 2016, Clinical Pharmacokinetics.
[5] H. Guchelaar,et al. Individualized dosing of tyrosine kinase inhibitors: are we there yet? , 2015, Drug discovery today.
[6] M. Tan,et al. Association of drug exposure with toxicity and clinical response in metastatic renal cell carcinoma patients receiving an attenuated dosing regimen of sunitinib , 2015, Targeted Oncology.
[7] A. Paci,et al. Review of therapeutic drug monitoring of anticancer drugs part two--targeted therapies. , 2014, European journal of cancer.
[8] S. Sleijfer,et al. Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours , 2014, British Journal of Cancer.
[9] M. Tan,et al. Role of sunitinib and SU12662 on dermatological toxicities in metastatic renal cell carcinoma patients: in vitro, in vivo, and outcomes investigation , 2014, Cancer Chemotherapy and Pharmacology.
[10] T. Miki,et al. A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety. , 2010, Japanese journal of clinical oncology.
[11] Dongwoo Kang,et al. A Population Pharmacokinetic Meta-analysis of Sunitinib Malate (SU11248) and Its Primary Metabolite (SU12662) in Healthy Volunteers and Oncology Patients , 2009, Clinical Cancer Research.
[12] E. Raymond,et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Juthamas Sukbuntherng,et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.